Skip to Content

Join the 'Anthrax' group to help and get support from people like you.

Anthrax News

Related terms: Anthrax, cutaneous, Anthrax, inhalation, Anthrax, skin, Cutaneous Anthrax, Inhalation Anthrax, Inhalation Bacillus anthracis, Ragpicker's disease, Wool sorter's disease

FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects

Posted 26 Jul 2016 by Drugs.com

ISSUE: FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). Includes the following currently available fluoroquinolones: Avelox (moxifloxacin) Cipro (ciprofloxacin) Cipro extended-release (ciprofloxacin extended-release) Factive (gemifloxacin) Levaquin (levofloxacin) Ofloxacin (generic brand) These medicines are ...

FDA Updates Warnings for Fluoroquinolone Antibiotics

Posted 26 Jul 2016 by Drugs.com

July 26, 2016 – The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. “Fluoroquinolones have risks and benefits that should be considered very c ...

Anthrax Vaccine Shows Promise in Monkey Trial

Posted 1 Jul 2016 by Drugs.com

FRIDAY, July 1, 2016 – A vaccine made with a component of the bacteria that causes anthrax protected monkeys from the deadly infection in a preliminary trial. Previous research showed that this component – the anthrax capsule – played a pivotal role in providing protection, the researchers said. In this study, the same team of scientists at the U.S. Army Medical Research Institute of ...

Inhalation Anthrax Treatment Anthim Approved

Posted 22 Mar 2016 by Drugs.com

MONDAY, March 21, 2016 – Anthim (obiltoxaximab) has been approved by the U.S. Food and Drug Administration to treat inhalational anthrax, a rare disease stemming from infected animal products. Bacillus anthracis spores also pose a deadly bioterrorism threat if released intentionally. Anthrax toxins can cause severe tissue damage and death, the FDA said Monday in a news release. Anthim, combined ...

FDA Approves Anthim (obiltoxaximab) for Inhalation Anthrax

Posted 22 Mar 2016 by Drugs.com

March 21, 2016 – On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Inhalational anthrax is a rare disease that can occur after exposure to ...

Anthrax Vaccine Approval Expanded

Posted 24 Nov 2015 by Drugs.com

TUESDAY, Nov. 24, 2015 – U.S. Food and Drug Administration approval for the BioThrax anthrax vaccine has been expanded to include adults aged 18 to 65 with known or suspected exposure, the agency said in a media release. The vaccine was first approved in 1970 for people at high risk of anthrax contact. Exposure to Bacillus anthracis bacteria, especially if inhaled, can cause death if not ...

FDA Approves BioThrax for Use After Known or Suspected Anthrax Exposure

Posted 23 Nov 2015 by Drugs.com

November 23, 2015 – The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was i ...

New Treatment for Anthrax Approved

Posted 26 Mar 2015 by Drugs.com

WEDNESDAY, March 25, 2015 – A new treatment to prepare the United States for the potential release of deadly inhalational anthrax has been approved by the U.S. Food and Drug Administration. Anthrasil (Anthrax Immune Globulin Intravenous) is sanctioned, when combined with approved antibiotics, to support the nation's preparedness against a possible anthrax attack, the FDA said Wednesday in a news ...

FDA Approves Anthrasil, [Anthrax Immune Globulin Intravenous (Human)], for Inhalation Anthrax

Posted 25 Mar 2015 by Drugs.com

March 25, 2015 – The U.S. Food and Drug Administration yesterday approved Anthrasil, Anthrax Immune Globulin Intravenous (Human), to treat patients with inhalational anthrax in combination with appropriate antibacterial drugs. Inhalational anthrax is a rare disease that can occur after exposure to infected animals or contaminated animal products, or as a result of an intentional release of ...

Pediatricians Should Plan for Anthrax Attack, U.S. Experts Say

Posted 28 Apr 2014 by Drugs.com

MONDAY, April 28, 2014 – Children may require different treatment than adults after exposure to anthrax, says a new report from leading U.S. pediatricians and health officials. Because of the danger posed by anthrax – a potential bioterrorism weapon – pediatricians need to be knowledgeable and prepared in order to minimize illness and death in the event of an anthrax release, says the report ...

FDA Approves Raxibacumab to Treat Inhalational Anthrax

Posted 17 Dec 2012 by Drugs.com

December 14, 2012 – The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. Raxibacumab is a monoclonal antibody that ...

Raxibacumab Approved for Inhalational Anthrax

Posted 17 Dec 2012 by Drugs.com

FRIDAY, Dec. 14 – Raxibacumab injection has been approved by the U.S. Food and Drug Administration to treat inhalational anthrax, an infectious disease caused by breathing in deadly anthrax spores, the agency said Friday. Raxibacumab neutralizes the toxins produced by the anthrax bacterium Bacillus anthracis. This infection can cause "massive and irreversible tissue injury and death," the FDA ...

Vulnerability to Anthrax Varies Widely: Study

Posted 6 Feb 2012 by Drugs.com

MONDAY, Feb. 6 – People's susceptibility to anthrax toxin is determined by their genes and can vary greatly among individuals, a new study says. Anthrax is an infectious disease widely regarded as a potential bioterrorism weapon. Stanford University School of Medicine researchers analyzed immune cells from 234 people and found that the cells of three of the people were virtually insensitive to ...

Anthrax Vaccine Shows Promise in Monkeys

Posted 22 Jan 2012 by Drugs.com

FRIDAY, Jan. 20 – Monkeys vaccinated with an anthrax capsule vaccine were protected against lethal anthrax infection, a new study has found. The anthrax capsule is a naturally occurring component of Bacillus anthracis, the bacterium that causes anthrax. This is the first successful use of a non-toxin vaccine to protect monkeys from anthrax, which is regarded as one of the most serious ...

Anthrax Attack Plans Need to Be Handled Locally, Report Says

Posted 30 Sep 2011 by Drugs.com

FRIDAY, Sept. 30 – Since the 9/11 tragedy and the anthrax scare that followed in its wake, Americans have lived with the potential threat of another, possibly more serious, anthrax attack. Now, a new report from the Institute of Medicine advises that plans for making antibiotics available to respond to a large-scale anthrax attack should be drawn up by local officials and based on the level of ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Bacterial Infection

Related Drug Support Groups

doxycycline, Cipro, ciprofloxacin, Levaquin, levofloxacin, Doryx, ofloxacin, moxifloxacin, Monodox, view more... chloramphenicol, Vibramycin, Doxy 100, gatifloxacin, Floxin, Chloromycetin, Morgidox, Doxy 200, Vibra-Tabs, Ocudox, Oraxyl, Floxin IV, Tequin Teqpaq, Pfizerpen, Anthrasil, Anthim, Levaquin Leva-Pak, Tequin, Doxy-Caps, Doxy-D, Chloracol, Cipro XR, Cipro IV, obiltoxaximab, anthrax immune globulin intravenous, penicillin g potassium, penicillin g sodium, raxibacumab, Doryx MPC